172 related articles for article (PubMed ID: 33425472)
21. Adjusting for treatment crossover in the MAVORIC trial: survival in advanced mycosis fungoides and Sézary syndrome.
Hawkins N; Muszbek N; Evans R; Dequen-O'Byrne P; Jones T; McNamara L
J Comp Eff Res; 2022 Aug; 11(11):805-813. PubMed ID: 35678206
[No Abstract] [Full Text] [Related]
22. An occurrence of eosinophilic folliculitis and alopecia associated with a sustained complete response to mogamulizumab in Sézary syndrome: a case report.
L'Orphelin JM
Ther Adv Hematol; 2024; 15():20406207241235777. PubMed ID: 38456078
[TBL] [Abstract][Full Text] [Related]
23. Understanding relative survival outcomes for patients with cutaneous T-cell lymphoma (CTCL) subtypes mycosis fungoides and Sézary syndrome treated with mogamulizumab or vorinostat: combining Australian real-world evidence and MAVORIC phase 3 trial data.
Remák E; Hawkins N; Jones T; Otley M; Twigger R; Prince M
Eur J Cancer; 2021 Oct; 156 Suppl 1():S18. PubMed ID: 34649645
[No Abstract] [Full Text] [Related]
24. Italian Real-Life Experience on the Use of Mogamulizumab in Patients with Cutaneous T-Cell Lymphomas.
Caruso L; Castellino A; Dessì D; Flenghi L; Giordano A; Ibatici A; Massone C; Pileri A; Proietti I; Pupo L; Quaglino P; Rupoli S; Zinzani PL
Cancer Manag Res; 2022; 14():3205-3221. PubMed ID: 36444356
[TBL] [Abstract][Full Text] [Related]
25. Mogamulizumab-induced vitiligo in patients with Sézary syndrome: three cases.
Algarni AS; Ram-Wolff C; Bagot M; De Masson A
Eur J Dermatol; 2021 Apr; 31(2):213-216. PubMed ID: 33814357
[TBL] [Abstract][Full Text] [Related]
26. Low-Dose Total Skin Electron Beam Therapy Combined With Mogamulizumab for Refractory Mycosis Fungoides and Sézary Syndrome.
Fong S; Hong EK; Khodadoust MS; Li S; Hoppe RT; Kim YH; Hiniker SM
Adv Radiat Oncol; 2021; 6(3):100629. PubMed ID: 33748543
[TBL] [Abstract][Full Text] [Related]
27. Effects of mogamulizumab in adult T-cell leukemia/lymphoma in clinical practice.
Sekine M; Kubuki Y; Kameda T; Takeuchi M; Toyama T; Kawano N; Maeda K; Sato S; Ishizaki J; Kawano H; Kamiunten A; Akizuki K; Tahira Y; Shimoda H; Shide K; Hidaka T; Kitanaka A; Yamashita K; Matsuoka H; Shimoda K
Eur J Haematol; 2017 May; 98(5):501-507. PubMed ID: 28152225
[TBL] [Abstract][Full Text] [Related]
28. Mogamulizumab efficacy is underscored by its associated rash that mimics cutaneous T-cell lymphoma: a retrospective single-centre case series.
Trum NA; Zain J; Martinez XU; Parekh V; Afkhami M; Abdulla F; Carson KR; Rosen ST; Bennett CL; Querfeld C
Br J Dermatol; 2022 Jan; 186(1):153-166. PubMed ID: 34427917
[TBL] [Abstract][Full Text] [Related]
29. A drug safety evaluation of mogamulizumab for the treatment of cutaneous T-Cell lymphoma.
Afifi S; Mohamed S; Zhao J; Foss F
Expert Opin Drug Saf; 2019 Sep; 18(9):769-776. PubMed ID: 31303060
[No Abstract] [Full Text] [Related]
30. Integrating novel systemic therapies for the treatment of mycosis fungoides and Sézary syndrome.
Prince HM; Querfeld C
Best Pract Res Clin Haematol; 2018 Sep; 31(3):322-335. PubMed ID: 30213403
[TBL] [Abstract][Full Text] [Related]
31. Novel and Future Therapeutic Drugs for Advanced Mycosis Fungoides and Sézary Syndrome.
Oka T; Miyagaki T
Front Med (Lausanne); 2019; 6():116. PubMed ID: 31192214
[TBL] [Abstract][Full Text] [Related]
32. Pharmaceutical Approval Update.
Choy M
P T; 2018 Oct; 43(10):599-628. PubMed ID: 30271102
[TBL] [Abstract][Full Text] [Related]
33. Effective treatment of mogamulizumab-induced head and neck dermatitis with fluconazole in a patient with peripheral T-cell lymphoma.
Asokan I; Singh S; Moesch J; Ho J; Akilov OE
JAAD Case Rep; 2022 Feb; 20():44-46. PubMed ID: 35036504
[No Abstract] [Full Text] [Related]
34. A Multicenter Retrospective Study of Mogamulizumab Efficacy in Adult T-Cell Leukemia/Lymphoma.
Iyama S; Sato T; Ohnishi H; Kanisawa Y; Ohta S; Kondo T; Mori A; Tsutsumi Y; Kuroda H; Kakinoki Y; Yamamoto S; Takahashi T; Shindo M; Torimoto Y; Sato K; Iwasaki H; Haseyama Y; Kohda K; Nagamachi Y; Hirayama Y; Sakai H; Hirata Y; Fukuhara T; Ikeda H; Kobune M; Kato J; Kurosawa M
Clin Lymphoma Myeloma Leuk; 2017 Jan; 17(1):23-30.e2. PubMed ID: 27727135
[TBL] [Abstract][Full Text] [Related]
35. IPH4102, a first-in-class anti-KIR3DL2 monoclonal antibody, in patients with relapsed or refractory cutaneous T-cell lymphoma: an international, first-in-human, open-label, phase 1 trial.
Bagot M; Porcu P; Marie-Cardine A; Battistella M; William BM; Vermeer M; Whittaker S; Rotolo F; Ram-Wolff C; Khodadoust MS; Bensussan A; Paturel C; Bonnafous C; Sicard H; Azim HA; Kim YH
Lancet Oncol; 2019 Aug; 20(8):1160-1170. PubMed ID: 31253572
[TBL] [Abstract][Full Text] [Related]
36. Total skin electron beam and non-myeloablative allogeneic hematopoietic stem-cell transplantation in advanced mycosis fungoides and Sezary syndrome.
Duvic M; Donato M; Dabaja B; Richmond H; Singh L; Wei W; Acholonu S; Khouri I; Champlin R; Hosing C
J Clin Oncol; 2010 May; 28(14):2365-72. PubMed ID: 20351328
[TBL] [Abstract][Full Text] [Related]
37. Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma.
Olsen EA; Kim YH; Kuzel TM; Pacheco TR; Foss FM; Parker S; Frankel SR; Chen C; Ricker JL; Arduino JM; Duvic M
J Clin Oncol; 2007 Jul; 25(21):3109-15. PubMed ID: 17577020
[TBL] [Abstract][Full Text] [Related]
38. Mogamulizumab-Associated Myositis With and Without Myasthenia Gravis and/or Myocarditis in Patients With T-Cell Lymphoma.
Virgen CA; Sparks JA; Nohria A; O'Hare MJ; Goyal A; Said JT; Tawa M; LeBoeuf NR; Kupper TS; Fisher DC; Larocca C
Oncologist; 2023 Aug; 28(8):e694-e698. PubMed ID: 37285523
[TBL] [Abstract][Full Text] [Related]
39. Outcome of allogeneic hematopoietic stem cell transplantation for mycosis fungoides and Sézary syndrome.
Mori T; Shiratori S; Suzumiya J; Kurokawa M; Shindo M; Naoyuki U; Katsuto T; Miyamoto T; Morishige S; Hirokawa M; Fukuda T; Atsuta Y; Suzuki R
Hematol Oncol; 2020 Aug; 38(3):266-271. PubMed ID: 32011008
[TBL] [Abstract][Full Text] [Related]
40. Prevalence and implications of mogamulizumab-induced immune-related adverse events in mycosis fungoides/Sézary syndrome; a single-center experience.
Jfri A; Virgen CA; Tawa M; Giobbie-Hurder A; Kupper TS; Fisher DC; LeBoeuf NR; Larocca C
J Am Acad Dermatol; 2023 Nov; 89(5):1044-1047. PubMed ID: 37321484
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
